ReviewPituitary2020
Dopamine agonist resistant prolactinomas: any alternative medical treatment?
Review in Pituitary, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Italian Guidelines for the Management of Prolactinomas.Endocrine, metabolic & immune disorders drug targets · 2023Guideline
- Surgical outcomes of medically failed prolactinomas: a systematic review and meta-analysis.Pituitary · 2021Pooled it
- Article
- Somatostatin 5 receptor expression in prolactinomas: Is there a role for Pasireotide in the management of prolactinomas?Pituitary · 2025Article
- Cabergoline-induced NDFIP1 upregulation in pituitary neuroendocrine tumor cells activates mTOR signaling and contributes to cabergoline resistance.Journal of neuro-oncology · 2025Article
- EndoCompass Project: Research Roadmap for Pituitary and Neuroendocrine Tumor Endocrinology.Hormone research in paediatrics · 2025Review
- Hormonally Active Pituitary Adenomas and Pregnancy: A Systematic Review.Medical journal of the Islamic Republic of Iran · 2025Review
- Prolactinoma: Navigating the Dual Challenge of Side Effects and Treatment Strategies - A Comprehensive Review.Annals of medicine and surgery (2012) · 2024Review
- Long-term use of clomiphene in male macroprolactinomas with persistent hypogonadism.Endocrine · 2024Article
- Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review.Journal of endocrinological investigation · 2024Review
- Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment.Frontiers in endocrinology · 2024Review
- Stereotactic Radiosurgery Outcomes in Medically and Surgically Failed or Nonsurgical Candidates with Medically Failed Prolactinomas: A Systematic Review and Meta-Analysis.Journal of neurological surgery. Part B, Skull base · 2023Article
- Approach to the Patient With Prolactinoma.The Journal of clinical endocrinology and metabolism · 2023Review
- Refractory lactotroph adenomas.Pituitary · 2023Review
- Effect of Tamoxifen on the Management of Dopamine Agonist-Resistant Prolactinomas: A Systematic Review.Cureus · 2023Review
- Current and Perspective Approaches to the Treatment of Prolactinomas.Acta medica Lituanic · 2023Review
- PER2 integrates circadian disruption and pituitary tumorigenesis.Theranostics · 2023Article
- The clinical and therapeutic profiles of prolactinomas associated with germline pathogenic variants in theFrontiers in endocrinology · 2023Article
- ACT001 inhibits pituitary tumor growth by inducing autophagic cell death via MEK4/MAPK pathway.Acta pharmacologica Sinica · 2022Article
- Treatment of Prolactinoma.Medicina (Kaunas, Lithuania) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Consensus guidelines recommend dopamine agonists (DAs) as the mainstay treatment for prolactinomas. In most patients, DAs achieve tumor shrinkage and normoprolactinemia at well tolerated doses. However, primary or, less often, secondary resistance to DAs may be also encountered representing challenging clinical scenarios. This is particularly true for aggressive prolactinomas in which surgery and radiotherapy may not achieve tumor control. In these cases, alternative medical treatments have been considered but data on their efficacy should be interpreted within the constraints of publication bias and of lack of relevant clinical trials. The limited reports on somatostatin analogues have shown conflicting results, but cases with optimal outcomes have been documented. Data on estrogen modulators and metformin are scarce and their usefulness remains to be evaluated. In many aggressive lactotroph tumors, temozolomide has demonstrated optimal outcomes, whereas for other cytotoxic agents, tyrosine kinase inhibitors and for inhibitors of mammalian target of rapamycin (mTOR), higher quality evidence is needed. Finally, promising preliminary results from in vitro and animal reports need to be further assessed and, if appropriate, translated in human studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.